1. Anterolateral entorhinal cortex thickness as a new biomarker for early detection of Alzheimer's disease
- Author
-
Jared M. Roberts, Andrew Holbrook, Freddie Márquez, Michael A. Yassa, Daniel L. Gillen, Alzheimer’s Disease Neuroimaging Initiative, and Nicholas J. Tustison
- Subjects
Pathology ,medicine.medical_specialty ,Disease status ,Amyloid ,Clinical Dementia Rating ,Early detection ,Neuroimaging ,brain imaging ,Disease ,lcsh:Geriatrics ,lcsh:RC346-429 ,Lesion ,memory ,03 medical and health sciences ,Cerebrospinal fluid ,0302 clinical medicine ,mild cognitive impairment ,Disease severity ,medicine ,lcsh:Neurology. Diseases of the nervous system ,030304 developmental biology ,ADNI‐1 ,0303 health sciences ,posteromedial entorhinal cortex ,receiver operating characteristic ,Receiver operating characteristic ,business.industry ,Alzheimer's disease ,cortical thickness ,Entorhinal cortex ,Psychiatry and Mental health ,lcsh:RC952-954.6 ,Mini‐Mental State Exam ,Biomarker (medicine) ,biomarker ,Neurology (clinical) ,medicine.symptom ,cerebrospinal fluid amyloid ,business ,anterolateral entorhinal cortex ,030217 neurology & neurosurgery ,Research Article ,linear mixed‐effects models - Abstract
IntroductionLoss of entorhinal cortex (EC) layer II neurons represents the earliest AD lesion in the brain. Research suggests differing functional roles between two EC subregions, the anterolateral EC (aLEC) and the posteromedial EC (pMEC).MethodsWe use joint label fusion to obtain aLEC and pMEC cortical thickness measurements from serial MRI scans of 775 ADNI-1 participants (219 healthy; 380 MCI; 176 AD) and use linear mixed-effects models to analyze longitudinal associations between cortical thickness, disease status and cognitive measures.ResultsGroup status is reliability predicted by aLEC thickness, which also exhibits greater associations with cognitive outcomes than does pMEC thickness. Change in aLEC thickness is also associated with CSF amyloid and tau levels.DiscussionThinning of aLEC is a sensitive structural biomarker that changes over short durations in the course of AD and tracks disease severity – it is a strong candidate biomarker for detection of early AD.
- Published
- 2020